Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease.
[More]
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
[More]
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
[More]
A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.
[More]
Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
[More]
House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.
[More]
In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).
[More]
Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.
[More]
Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas.
[More]
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.
[More]
Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market.
[More]
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
[More]
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.
[More]
A network of five leading medical centers, led by Cincinnati Children's Hospital Medical Center and Boston Children's Hospital, has received a five-year, $12.5 million National Institutes of Health (NIH) grant to learn more about how autism develops.
[More]
Results from two phase III trials demonstrate significantly better skin lesion reduction with everolimus than placebo in patients with tuberous sclerosis complex.
[More]
Stent fracture after everolimus-eluting stent implantation occurs in 2.9% of lesions and is associated with a significantly increased rate of major adverse cardiac events, say researchers.
[More]
Stent fracture after everolimus-eluting stent implantation occurs in 2.9% of lesions and is associated with a significantly increased rate of major adverse cardiac events, say researchers.
[More]
The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.
[More]
Seattle Genetics, Inc. today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor) for patients with advanced metastatic renal cell carcinoma (RCC).
[More]
Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.
[More]